How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes

INTRODUCTION: Lack of control in diabetic patients has stimulated the development of new insulin analogues. One of these was basal insulin peglispro (BIL) or LY2605541; it had a large hydrodynamic size, flat pharmacokinetic profile, half life of 2–3 days and acted preferably in the liver. METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Garach, Araceli, Molina-Vega, María, Tinahones, Francisco J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306113/
https://www.ncbi.nlm.nih.gov/pubmed/27896568
http://dx.doi.org/10.1007/s13300-016-0214-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306113/
https://www.ncbi.nlm.nih.gov/pubmed/27896568
http://dx.doi.org/10.1007/s13300-016-0214-7

Ejemplares similares